Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Victoria A Kriuchkovskaia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical & Biomolecular Engineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Hydrogels, Gelatin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Chemical & Biomolecular Engineering and Cancer Center at Illinois at the University of Illinois at Urbana-Champaign, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Acquired drug resistance in glioblastoma (GBM) presents a major clinical challenge and is a key factor contributing to abysmal prognosis, with less than 15 months median overall survival. Aggressive chemotherapy with the frontline therapeutic, temozolomide (TMZ), ultimately fails to kill residual highly invasive tumor cells after surgical resection and radiotherapy. Here, a 3D engineered model of acquired TMZ resistance is reported using two isogenically matched sets of GBM cell lines encapsulated in gelatin methacrylol hydrogels. Response of TMZ‐resistant versus TMZ‐sensitive GBM cell lines within the gelatin‐based extracellular matrix platform is benchmarked and drug response at physiologically relevant TMZ concentrations is further validated. The changes in drug sensitivity, cell invasion, and matrix‐remodeling cytokine production are shown as the result of acquired TMZ resistance. This platform lays the foundation for future investigations targeting key elements of the GBM tumor microenvironment to combat GBM's devastating impact by advancing the understanding of GBM progression and treatment response to guide the development of novel treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical & Biomolecular Engineering, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
- Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
- Department of Oncology, Lombardi Comprehensive Cancer Center, University Medical Center, Washington, DC, 20007, USA.
- Cancer Center at Illinois, University of Illinois Urbana-Champaign, Urbana, IL, 61801, USA.
ORCID-Profile: Brendan A C Harley
Förderung
- Department of Chemical & Biomolecular Engineering and Cancer Center at Illinois at the University of Illinois at Urbana-Champaign
- NIH HHS
- NCI NIH HHS
- Carl R. Woese Institute for Genomic Biology
- NIBIB NIH HHS
- National Institutes of Health
Zitieren
APA
Kriuchkovskaia, V. A., Eames, E. K., Riggins, R. B., & Harley, B. A. C. (2024). Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400779
Vancouver
Kriuchkovskaia VA, Eames EK, Riggins RB, Harley BAC. Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400779
BibTeX
@article{Kriuchkovskaia2024,
author = {Kriuchkovskaia, Victoria A and Eames, Ela K and Riggins, Rebecca B and Harley, Brendan A C},
title = {Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400779}
}
EUVIMED